97 related articles for article (PubMed ID: 2314831)
1. Phase II study of pirarubicin (THP-adriamycin) in metastatic breast cancer patients.
Lenk H; Tanneberger S; Wiener N; Giesske H; Gärtner S; Geyer J; Rotte KH
Oncology; 1990; 47(2):97-100. PubMed ID: 2314831
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of pirarubicin in metastatic breast cancer.
Kleeberg UR; Reichel L; Wander HE; Beyer JH; Essers U; Fiebig HH; Salewski E; Greifenberg B; Edler L
Onkologie; 1990 Jun; 13(3):175-9. PubMed ID: 2204003
[TBL] [Abstract][Full Text] [Related]
4. Pirarubicin (4'-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. A Clinical Phase II study.
Scheithauer W; Samonigg H; Depisch D; Schüller J; Hausmaninger H; Wiegele J; Zielinsky C; Stöger H; Haider K; Preis P
Invest New Drugs; 1990 May; 8(2):207-10. PubMed ID: 2384308
[TBL] [Abstract][Full Text] [Related]
5. An oriented phase II trial of THP-adriamycin in breast carcinoma.
Mathé G; Umezawa H; Oka S; Misset JL; Brienza S; de Vassal F; Musset M; Ribaud P; Tapiero H
Biomed Pharmacother; 1986; 40(10):376-9. PubMed ID: 3580506
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II study on weekly administration of pirarubicin in patients with metastatic breast cancer.
Dittrich C; Baur M; Mader R; Schlappack O; Dudczak R; Leitha T; Lenzhofer R; Hoffmann S; Vieder L; Heberle U
Am J Clin Oncol; 1990; 13 Suppl 1():S29-39. PubMed ID: 1963274
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer.
Chevallier B; Mignot L; Delozier T; Morvan F; Ferme C; Herait P
Am J Clin Oncol; 1992 Oct; 15(5):395-8. PubMed ID: 1524040
[TBL] [Abstract][Full Text] [Related]
8. 4'-O-tetrahydropyranyl-doxorubicin in advanced breast cancer: a phase II study.
Samonigg H; Kasparek AK; Stöger H; Schmid M; Eber B; Stark G; Weinrauch V; Pfeiffer K; Smola M; Steindorfer P
Cancer Chemother Pharmacol; 1990; 26(4):293-6. PubMed ID: 2369794
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients.
Kolarić K; Mechl Z; Potrebica V; Sopkova B
Oncology; 1987; 44(2):82-6. PubMed ID: 3472133
[TBL] [Abstract][Full Text] [Related]
10. [Phase II study of THP (2''R)-4'-0-tetrahydropyranyladriamycin) in breast cancer].
Abe O; Enomoto K; Tominaga T; Kasai Y; Soejima S; Kasai M; Izuo M; Yoshida M; Kubo K; Terasawa T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):578-85. PubMed ID: 3954379
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
Stöger H; Bauernhofer T; Schmid M; Ploner F; Moser R; Derstvenscheg E; Steindorfer P; Wilders-Truschnig M; Kuss I; Samonigg H
Cancer Chemother Pharmacol; 1994; 35(2):174-8. PubMed ID: 7987997
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).
Chauvergne J; Fumoleau P; Cappelaere P; Metz R; Armand JP; Chevallier B; Kerbrat P; de Forni M; Lhommé C; Roche H
Eur J Cancer; 1993; 29A(3):350-4. PubMed ID: 8398333
[TBL] [Abstract][Full Text] [Related]
13. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma.
Sridhar KS; Hussein AM; Benedetto P; Ardalan B; Savaraj N; Richman SP
Cancer; 1992 Sep; 70(6):1591-7. PubMed ID: 1516010
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of pirarubicin in malignant pleural mesothelioma.
Kaukel E; Koschel G; Gatzemeyer U; Salewski E
Cancer; 1990 Aug; 66(4):651-4. PubMed ID: 2386894
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
17. Pirarubicin in advanced breast cancer: a French cooperative phase II study.
Spielmann M; Kerbrat P; Delozier T; Fumoleau P; Monnier A; Chevallier B; Bastit P; Namer M; Cattan A; Lucas P
Eur J Cancer; 1990; 26(7):821-3. PubMed ID: 2145903
[TBL] [Abstract][Full Text] [Related]
18. A preliminary analysis of combination therapy with vincristine, adriamycin, and prednimustine (VAP) in advanced breast cancer: a phase II study.
Lehnert M; Biffl G; Wascher H; Jordis-Lohausen K; Wählby S
Semin Oncol; 1986 Mar; 13(1 Suppl 1):32-4. PubMed ID: 3754064
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of iproplatin in metastatic breast carcinoma.
Hortobagyi GN; Frye D; Holmes FA; Hug V; Fraschini G; Buzdar AU
Cancer Treat Rep; 1987 Dec; 71(12):1193-6. PubMed ID: 3690529
[TBL] [Abstract][Full Text] [Related]
20. Phase II trials of tetrahydropyranyl-adriamycin (Pirarubicin) on renal and colon carcinoma, melanoma, and soft tissue sarcoma.
Roché H; Guiochet N; Kerbrat P; Rebattu P; Fargeot P; Cattan A; Armand JP; Keiling R; Lentz MA; Van Glabeke M
Am J Clin Oncol; 1993 Apr; 16(2):137-9. PubMed ID: 8452105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
